EUVIMEDObjevte EUVIMED
KohortenstudieOpen access

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study

Acacia C Parks iD, Amanda L Woodward iD, Robert D Henry iD, Kristin A Arden iD, Leonardo Vando iD, Jack Swain iD, Bishal Lamichhane iD

Journal of Medical Internet Research · 2026-07-20 · 28 · e92647

DOI: 10.2196/92647 ↗

At a glance

Kohortenstudie in Journal of Medical Internet Research, published online on 2026-07-20. Written by Acacia C Parks and 6 co-authors. Institution: Liquid Amber, Watertown, MA, United States. Major MEDLINE topics: Ketamine, Stress Disorders, Post-Traumatic, Telemedicine, Depression. 58 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Depression, anxiety, and posttraumatic stress disorder (PTSD) are leading global causes of disability. Standard interventions have slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual at-home ketamine addresses some gaps but is constrained by low bioavailability and variable absorption. Subcutaneous administration offers high bioavailability and precise dosing, potentially bridging the gap between in-clinic effectiveness and at-home accessibility.

Objective

This study evaluated the safety, feasibility, and clinical outcomes of a telehealth, at-home subcutaneous ketamine protocol using a convenience sample of deidentified health records collected through Mindbloom’s telehealth platform across 38 states.

Methods

This retrospective cohort study analyzed deidentified health records from 3870 patients with moderate to severe symptoms of depression (Patient Health Questionnaire-9 [PHQ-9] score≥10), anxiety (Generalized Anxiety Disorder-7 Scale [GAD-7] score≥10), or PTSD (PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition; PCL-5] ≥33). Participants completed a structured program involving clinical assessment, mandatory peer monitoring, remote physiological screening, mailed injection kits and blood pressure monitors, and clinician-guided subanesthetic dosing starting at 0.5 mg/kg. Primary outcomes were measured at baseline and after weeks 2, 4, and 6 using the PHQ-9, GAD-7, and PCL-5. Linear mixed effects models with cubic splines analyzed symptom trajectories and accounted for time-varying assessments. Statistical significance was defined as α=.05; effect sizes were reported. Sensitivity analyses used multiple imputation and last observation carried forward.

Results

Patients (mean age 44.7, SD 10.8 years; 1592/3041, 52.4% female) demonstrated high adherence, with 0.5% (16/3041) switching from subcutaneous to sublingual administration. After 6 sessions (approximately 44 days), adjusted marginal means showed significant declines: PHQ-9 scores dropped from 14.64 (95% CI 13.99-15.29) to 6.30 (95% CI 5.90-6.70), GAD-7 from 13.06 (95% CI 12.45-13.67) to 6.09 (95% CI 5.72-6.47), and PCL-5 from 46.7 (95% CI 43.30-50.10) to 27.5 (95% CI 25.40-29.70) with large effect sizes (1.35-1.58). Minimal clinically important difference was achieved by 81.8% (603/737) patients with major depressive disorder, 80% (475/594) with generalized anxiety disorder, and 84.6% (203/240) with PTSD (P

Subjects

MeSH terms (MEDLINE)

KetamineStress Disorders, Post-TraumaticTelemedicineDepressionAnxietyHumansRetrospective StudiesFemaleMaleAdultMiddle AgedUnited StatesFeasibility StudiesTreatment OutcomeInjections, SubcutaneousCohort Studies

Author keywords

PTSDdigital healthgeneralized anxiety disorderketaminemajor depressive disordermental healthposttraumatic stress disorderpsychedelicreal-worldtelemedicine

Substances

Ketamine

Authors and institutions

  • Liquid Amber, Watertown, MA, United States.
  • TSET Health Promotion Research Center, University of Oklahoma Health Sciences Center, Tulsa, OK, United States.
  • Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Tulsa, OK, United States.
  • Mindbloom, Orlando, FL, United States.
  • Department of Psychiatry and Behavioral Health, Houston Methodist Academic Institute (HMAI), Houston Methodist, Houston, TX, United States.

ORCID profiles: Acacia C Parks, Amanda L Woodward, Robert D Henry, Kristin A Arden, Leonardo Vando, Jack Swain, Bishal Lamichhane

Cite

APA

Parks, A. C., Woodward, A. L., Henry, R. D., Arden, K. A., Vando, L., Swain, J., & Lamichhane, B. (2026). At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study. Journal of Medical Internet Research, 28, e92647. https://doi.org/10.2196/92647

Vancouver

Parks AC, Woodward AL, Henry RD, Arden KA, Vando L, Swain J, et al. At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study. Journal of Medical Internet Research. 2026;28:e92647. doi:10.2196/92647

BibTeX
@article{Parks2026,
  author = {Parks, Acacia C and Woodward, Amanda L and Henry, Robert D and Arden, Kristin A and Vando, Leonardo and Swain, Jack and Lamichhane, Bishal},
  title = {At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study},
  journal = {Journal of Medical Internet Research},
  year = {2026},
  volume = {28},
  pages = {e92647},
  doi = {10.2196/92647}
}
Start for free →